-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41

Benzinga·08/07/2026 13:12:29
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $34 to $41.